Free tool
Oncology stocks
We cover 30 companies grouped under the Oncology theme. The median market value in the group is $4.56B. Across the group, the median move over the past trading day is −0.78%. 87% of the 30 with a 200-day average trade above it. Price change over the past year runs from +8.9% to +447.2% across the middle 80 percent of the group, with a median of +115.7%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
30 of 319 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| MRK | Merck & Co., Inc. | $377.72B | Mega cap | +86.85% | Oct 29, 2026 |
| AZN | AstraZeneca PLC | $263.12B | Mega cap | +5.09% | Oct 30, 2026 |
| BMY | Bristol-Myers Squibb Company | $138.03B | Large cap | +47.01% | Oct 29, 2026 |
| RVMD | Revolution Medicines, Inc. | $46.18B | Large cap | +466.35% | Nov 4, 2026 |
| ONC | BeOne Medicines AG | $42.58B | Large cap | +25.21% | Nov 5, 2026 |
| BNTX | BioNTech SE | $28.28B | Large cap | +9.27% | Nov 3, 2026 |
| INCY | Incyte Corporation | $25.97B | Large cap | +51.01% | Oct 27, 2026 |
| GMAB | Genmab A/S | $21.42B | Large cap | +36.20% | Nov 5, 2026 |
| EXEL | Exelixis, Inc. | $14.05B | Large cap | +45.68% | Oct 27, 2026 |
| SMMT | Summit Therapeutics Inc. | $11.35B | Large cap | −42.63% | Oct 19, 2026 |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% | Nov 9, 2026 |
| ERAS | Erasca, Inc. | $6.70B | Mid cap | +1112.03% | Nov 11, 2026 |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +77.38% | Nov 5, 2026 |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +196.85% | Nov 3, 2026 |
| CELC | Celcuity Inc. | $4.65B | Mid cap | +90.31% | Nov 11, 2026 |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% | Nov 11, 2026 |
| TNGX | Tango Therapeutics, Inc. | $4.29B | Mid cap | +269.13% | Nov 4, 2026 |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | +445.10% | Nov 5, 2026 |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% | Nov 9, 2026 |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% | Oct 27, 2026 |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +188.94% | Nov 5, 2026 |
| ZLAB | Zai Lab Limited | $2.92B | Mid cap | −20.06% | Nov 5, 2026 |
| SLS | SELLAS Life Sciences Group, Inc. | $2.77B | Mid cap | +615.10% | Nov 11, 2026 |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% | Oct 8, 2026 |
| NUVB | Nuvation Bio Inc. | $2.44B | Mid cap | +135.93% | Nov 2, 2026 |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% | Sep 29, 2026 |
| URGN | UroGen Pharma Ltd. | $2.25B | Mid cap | +135.11% | Nov 5, 2026 |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | +254.61% | Nov 4, 2026 |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% | Nov 5, 2026 |
| NVCR | NovoCure Limited | $2.08B | Mid cap | +50.21% | Oct 29, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.